5:34 PM
Jun 08, 2017
 |  BC Extra  |  Clinical News

Team describes off-target effects of Bial's FAAH inhibitor

In a paper published in Science, researchers characterized off-target activities of fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 that they say may have played a role in the compound’s clinical neurotoxicity that led to the death of one participant in a Phase I trial, and caused brain damage in others. The group said the compound inhibited lipases another FAAH inhibitor did not.

Bial-Portela & Ca. S.A. (S. Mamede...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >